CELYAD ONCOLOGY SA Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2021-11-22: Study NCT04991948; Company role Lead sponsor; Phase Phase 1; Status Recruiting.
- 2020-11-16: Study NCT04613557; Company role Lead sponsor; Phase Phase 1; Status Active not recruiting.
- 2019-11-25: Study NCT04167696; Company role Lead sponsor; Phase Phase 1; Status Recruiting.
- 2018-12: Study NCT03612739; Company role Lead sponsor; Phase Phase 1; Status Withdrawn.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2021-11-22 | NCT04991948 Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer | Lead sponsor | Phase 1 | Recruiting | Unresectable Metastatic Colorectal Cancer | 34 | 2038-05-25 |
| 2020-11-16 | NCT04613557 Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma | Lead sponsor | Phase 1 | Active not recruiting | Relapse/Refractory Multiple Myeloma | 18 | 2037-02 |
| 2019-11-25 | NCT04167696 Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 | Lead sponsor | Phase 1 | Recruiting | Acute Myeloid Leukemia; Myelodysplastic Syndrome | 27 | 2035-02 |
| 2018-12 | NCT03612739 EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 | Lead sponsor | Phase 1 | Withdrawn | AML, Adult; Myelodysplastic Syndromes | 0 | 2021-08 |
| 2018-11-28 | NCT03692429 alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | Lead sponsor | Phase 1 | Recruiting | Unresectable Metastatic Colorectal Cancer | 49 | 2036-02-17 |
| 2018-09-18 | NCT03466320 DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 | Lead sponsor | Phase 1, Phase 2 | Completed | AML; MDS | 21 | 2021-02-01 |
| 2017-10-11 | NCT03370198 Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer | Lead sponsor | Phase 1 | Terminated | Colon Cancer Liver Metastasis | 1 | 2018-12-15 |
| 2017-08-07 | NCT03310008 Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases | Lead sponsor | Phase 1 | Unknown | Colon Cancer Liver Metastasis | 36 | 2021-05 |
| 2017-06 | NCT02317458 Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL | Lead sponsor | Phase 3 | Unknown | Heart Failure | 400 | |
| 2016-12 | NCT03018405 A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications | Lead sponsor | Phase 1, Phase 2 | Unknown | Acute Myeloid Leukemia/Myelodysplastic Syndrome; Multiple Myeloma (MM) | 146 | 2021-08 |
| 2015-03 | NCT02203825 Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | Lead sponsor | Phase 1 | Completed | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Multiple Myeloma | 12 | 2018-03 |
| 2012-11 | NCT01768702 Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure. | Lead sponsor | Phase 3 | Completed | Heart Failure | 315 | 2017-08 |
| 2008-12 | NCT00810238 C-Cure Clinical Trial | Lead sponsor | Phase 2, Phase 3 | Completed | Heart Failure Class II or III | 240 | 2012-01 |